Please provide your email address to receive an email when new articles are posted on . Researchers trained a convolutional neural network with ECGs from patients with COPD and controls to detect COPD ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer—has long captured the public imagination. Yet most arguments about it rest ...

It’s a simple question that physicians usually do not ask their patients: “When was your last drink?” “If the patient says yesterday, you know the patient isn’t a casual drinker,” said Joe G. Zein, MD ...

In support of World COPD Day on November 19, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is drawing attention to the importance of correctly diagnosing COPD earlier - with the ...

The true nature of our universe as been an open debate for millennia, and recently, scientists and philosophers have pondered whether it might be a hyper-realistic simulation perpetuated by some super ...

Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many of the drawbacks of current drugs, and it has come from an unexpected place.

“This new COPD diagnostic schema, which includes chest imaging, respiratory symptoms and spirometry, identified additional individuals at risk of poor respiratory outcomes,” said Bhatt, a professor in ...

COPD affects at least 4.5% of those 18-49 years old, according to an analysis of U.S. cohorts. The early COPD group was more likely to be hospitalized or die from chronic respiratory disease, to ...

Biologic medicines are making inroads into chronic obstructive pulmonary disease (COPD), with two blockbuster antibodies expanding their FDA-approved uses to this lung disorder in the past year. A ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...